Axplora’s Chasse-sur-Rhône CDMO site in France has successfully passed its latest on-site inspection by the French National Agency for Medicines and Health Products Safety (ANSM).

Conducted in February 2025, the inspection confirmed the site’s full compliance with current Good Manufacturing Practices (cGMP), with no critical remarks or 483 observations. This achievement marks the ninth successful inspection at Chasse-sur-Rhône since 2003 and underscores Axplora’s unwavering commitment to regulatory rigor and operational reliability.

“This achievement is the result of our team’s quality, safety, and operational excellence mindset, all delivered with reliability, speed, and efficiency,” said Daniel Lasanow, Site Director. “We are proud to provide a trusted, fully compliant environment that supports our customers’ API development from early-phase projects through to commercial supply.”

With more than 30 clinical and commercial small molecules, the Chasse-sur-Rhône site plays a central role in Axplora’s integrated European CDMO network, which includes five sites with a 100% regulatory inspection success rate. Together, these facilities deliver capabilities for custom development and manufacturing of APIs and intermediates. They also ensure flexibility, scalability, and robust supply for pharmaceutical innovators worldwide, from small-scale to large-scale quantities, throughout the entire product lifecycle.